Advanced Micro Devices, Inc. (AMD), And 3 Stocks to Buy After Last Week’s Earnings

A Stock that May Have Reached the Bottom of its Decline

Advanced Micro Devices, Inc. (NYSE:AMD) closed on Friday with a loss of 1.59% after reporting earnings, but on Thursday had seen a late push higher for gains of almost 10%. During the last week the stock was flat, and this occurred despite earnings that beat expectations. Yet despite this beat, revenue declined 31% yoy and the company’s gross margins continue to show significant weakness.

The weak PC market combined with AMD’s lost share in the industry has contributed to the stock’s large 70% decline over the last year. Thankfully, all of its problems are appropriately priced into its valuation, and for the first time, AMD saw some real progress.

First off, I was highly encouraged that the company beat expectations. Second, the company raised Q2 guidance. Third, server CPU revenue rose quarter-over-quarter. Lastly, the company stated that it is regaining desktop GPU share. These facts combined with an underperforming stock trading at just 0.38 times sales, gives me reason to be bullish, and believe that AMD might just be worth the risk.


“When a stock trades lower following a great report, it may be your best opportunity to buy.” Taking Charge With Value Investing (McGraw-Hill, 2013)

The key to successfully trading the reactions to earnings is to first read the report and to then look at a stock’s reaction. Then, you can find inconsistencies, and profit from those inconsistencies. With these three companies, all posted solid quarters relative to their valuations, and because of that fact, I believe that each presents some level of upside from this point forward.

The article 3 Stocks to Buy After Last Week’s Earnings originally appeared on

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!